George Zavoico


MLV Maintains Buy On Pluristem Following NIH Trial Results Of PLX-R18

In a research report sent to investors today, MLV analyst George Zavoico maintained a Buy rating on Pluristem Therapeutics (NASDAQ:PSTI) with a $6.00 …

MLV Pounds The Table On Omeros Corporation

MLV analyst George Zavoico was out pounding the table on Omeros (NASDAQ:OMER) Wednesday, reiterating a Buy rating and a price target of $38.00, which implies …

MLV Reiterates Buy On Cytokinetics Following 4Q:14 Update

In a research report sent to investors today, MLV analyst George Zavoico reiterated a Buy rating on Cytokinetics, Inc. (NASDAQ:CYTK) with a $9.

MLV Raises Agenus Price Target Following Multi-Year Partnership Agreement With Incyte

In a research report released Friday, MLV analyst George Zavoico reiterated a Buy rating on Agenus (NASDAQ:AGEN) and raised his price target to $9.00 …

MLV Sees Increasing Likelihood Of Keryx’s Auryxia Approval; Raises Price Target

In a research report issued today, MLV analyst George Zavoico maintained a Buy rating on Keryx Biopharmaceuticals (NASDAQ:KERX) and raised his price target …

MLV Maintains Buy On Cerus Following Phase II Results Of INTERCEPT Red Blood Cells

In a research report released today, MLV analyst George Zavoico reiterated a Buy rating on Cerus (NASDAQ:CERS) with a price target of $10, …

UPDATE: MLV Reiterates Bullish Stance On Cerus Following Two FDA Approvals In A Week

Just two days after approving Cerus’ (NASDAQ:CERS) INTERCEPT Blood System for Plasma, the FDA comes through and approves INTERCEPT Blood System for Platelets.  …

MLV Reiterates Buy On Agenus Following Positive Outcome Of Phase 3 Study Of GSK Shingles Vaccine

In a research report sent to investors today, MLV analyst George Zavoico reiterated a Buy rating on Agenus (NASDAQ:AGEN) with a $6.00 price …

Threshold Stock Is Currently Undervalued, Says MLV Analyst

In a research report issued today, MLV analyst George Zavoico reiterated a Buy rating on Threshold Pharmaceuticals (NASDAQ:THLD) with a $14.50 price target, …

UPDATE: MLV Raises Cerus Price Target On The Back Of FDA Approval

MLV analyst George Zavoico is out again today with a new research note on Cerus (NASDAQ:CERS), raising his price target to $10 (from $7), while maintaining a …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts